東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Renal pharmacotherapy = dosage adjus...

Golightly, Larry K.

Linked to FindBook

Google Book

Amazon

博客來

Renal pharmacotherapy = dosage adjustment of medications eliminated by the kidneys /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Renal pharmacotherapy/ by Larry K. Golightly ... [et al.].
Reminder of title:	dosage adjustment of medications eliminated by the kidneys /
other author:	Golightly, Larry K.
Published:	Cham :Springer International Publishing : : 2021.,
Description:	xxvi, 827 p. :ill., digital ;24 cm.
[NT 15003449]:	A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
Contained By:	Springer Nature eBook
Subject:	Renal pharmacology. -
Online resource:	https://doi.org/10.1007/978-3-030-58650-8
ISBN:	9783030586508

Renal pharmacotherapy = dosage adjustment of medications eliminated by the kidneys /
Renal pharmacotherapydosage adjustment of medications eliminated by the kidneys /[electronic resource] :by Larry K. Golightly ... [et al.]. - Second edition. - Cham :Springer International Publishing :2021. - xxvi, 827 p. :ill., digital ;24 cm.

A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.

ISBN: 9783030586508

Standard No.: 10.1007/978-3-030-58650-8doiSubjects--Topical Terms:

833146
Renal pharmacology.

LC Class. No.: RM145

Dewey Class. No.: 615.19

Renal pharmacotherapy = dosage adjustment of medications eliminated by the kidneys /
LDR:02743nmm a2200337 a 4500 001 2251511
003 DE-He213
005 20210924160542.0
006 m d
007 cr nn 008maaau
008 220215s2021 sz s 0 eng d
020 $a 9783030586508 $q (electronic bk.)
020 $a 9783030586492 $q (paper)
024 7 $a 10.1007/978-3-030-58650-8 $2 doi
035 $a 978-3-030-58650-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RM145
072 7 $a MJR $2 bicssc
072 7 $a MED055000 $2 bisacsh
072 7 $a MJR $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM145 $b .R393 2021
245 0 0 $a Renal pharmacotherapy $h [electronic resource] : $b dosage adjustment of medications eliminated by the kidneys / $c by Larry K. Golightly ... [et al.].
250 $a Second edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xxvi, 827 p. : $b ill., digital ; $c 24 cm.
505 0 $a A: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
520 $a To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
650 0 $a Renal pharmacology. $3 833146
650 0 $a Drugs $x Dosage. $3 916658
650 0 $a Drugs $x Metabolism. $3 683549
650 1 4 $a Nephrology. $3 894870
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Internal Medicine. $3 858559
650 2 4 $a Pharmacotherapy. $3 1978501
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Drug Resistance. $3 836316
700 1 $a Golightly, Larry K. $3 3518586
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-58650-8
950 $a Medicine (SpringerNature-11650)